Skip to main content
TipRanks
Go Ultimate75% OFF

Lumos Diagnostics Holdings Ltd. (LDX) Q2 2026 Earnings Report

28 Followers

AU:LDX Q2 2026 EPS Results

Actual EPS
-AUD 0.01
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-AUD 0.01

AU:LDX Q2 2026 Revenue Results

Actual Revenue
AUD 9.34M
Expected Revenue
AUD 3.85M
Beat/Miss
Beat by +AUD 5.49M
YoY Revenue Growth
-2.10%

Earnings Announcement Details

Quarter
Q2 2026
Date
02/26/2026
Time
After Close
Conference Call
Thursday, February 26, 2026
AU:LDX Upcoming Earnings

Lumos Diagnostics Holdings Ltd.'s next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Feb 26, 2026|% Change Since:-72.55%|
Earnings Call Sentiment|Positive

The call was broadly positive: management secured a material exclusive U.S. distribution agreement (USD 317M minimum), completed and submitted the CLIA waiver study while expressing near-term optimism about approval, achieved strong product revenue growth and high gross margins, and materially improved cash flow and adjusted EBITDA versus prior years. Key risks remain including an outstanding CLIA waiver approval (which drives the commercial ramp), continued adjusted EBITDA losses, declines in IP/services revenue timing, and the need for incremental manufacturing capacity and near-term financing actions. Overall, the highlights (large distribution deal, reimbursement, margin improvement, improved cash flow, nondilutive funding and product momentum) outweigh the lowlights tied mainly to timing, conditionality of the waiver, and continued operating losses.

Company Guidance

Management guided that CLIA‑waiver for FebriDx is expected imminently (targeted in March), which would activate the 6‑year U.S. exclusive PHASE distribution deal guaranteeing a minimum USD 317 million in sales to Lumos (PHASE paid a USD 1.0m exclusivity fee in H1 and is expected to prepay USD 5.0m on waiver), and highlighted that FebriDx has Medicare/MAC reimbursement of USD 41.38 per test (seven MACs agreed); BARDA‑funded pediatric work (~USD 6.2m) should add ~20% to the addressable market with the pediatric trial expected to finish by year‑end. Financial guidance reinforced H1 FY26 results: revenue USD 6.1m (products USD 1.7m vs USD 0.8m prior, services USD 4.4m vs USD 5.5m), IP revenue USD 1.0m (vs 2.6m), gross profit USD 4.2m and 68% gross margin, adjusted EBITDA loss USD 1.4m (improved from a USD 4.2m loss in H1 FY24), operating cash flow +USD 0.1m (vs -6.8m), BARDA receipts USD 2.8m, and liquidity support with USD 1.0m drawn on a finance facility (USD 4.0m remaining); management said current manufacturing capacity can meet expected PHASE demand for the first two years but will require investment to scale thereafter.

  • Secured Major U.S. Distribution Agreement (PHASE)Signed a 6-year exclusive U.S. distribution agreement for FebriDx with PHASE Scientific that guarantees a minimum of USD 317 million in sales to Lumos over the term; PHASE also paid a USD 1.0 million exclusivity fee recognized in H1 revenue.
  • CLIA Waiver Study Completed and SubmittedCompleted the CLIA waiver study in August and submitted to the U.S. FDA; management is optimistic a CLIA waiver grant will be announced imminently (targeted for March), which would materially expand addressable market and in-office use.
  • Reimbursement SecuredSecured Medicare/Medicaid reimbursement set by CMS at USD 41.38 per test with seven MACs agreeing to pay full reimbursement, improving the economics and adoption potential for FebriDx in physician offices.
  • Revenue and Product Revenue GrowthReported first half revenue of USD 6.1 million; product revenue was USD 1.7 million vs USD 0.8 million in prior corresponding period, representing approximately a +112.5% increase year-over-year (driven largely by FebriDx).
  • Strong Gross Profit and Margin ImprovementGross profit of USD 4.2 million and a gross margin of 68%, up 1 percentage point on the prior corresponding period and up 13 percentage points versus two years ago; FebriDx product margin indicated north of 60%.
  • Improved Cash Flow and Nondilutive FundingOperating cash flow turned positive at USD 0.1 million in H1 versus an outflow of USD 6.8 million in the prior corresponding period; received USD 2.8 million in BARDA funding during H1 and secured ~USD 6.2 million to fund the pediatric trial. Management emphasized nondilutive financing actions (BARDA, IP arrangements, sale-leaseback, investor loan facility).
  • Reduction in Losses vs Prior YearsAdjusted EBITDA loss improved to USD 1.4 million in H1 (slightly worse than the immediate prior period but a significant improvement from FY24 H1 loss of USD 4.2 million), indicating progress toward profitability.
  • Services Business Performing and Backfilled RevenueServices revenue of USD 4.4 million with ongoing project work (~14 projects recently), cash-flow positive services segment and new contract wins (e.g., Aptatek) that help offset reduced IP revenue recognition.
  • Pediatric Study Funding and Label ExpansionSecured funding (~USD 6.2 million) to run a pediatric trial to extend FebriDx label to ages 2–12; trial expected to complete by end of the calendar year and expand market by an estimated ~20%.

AU:LDX Earnings History

AU:LDX earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272027 (Q2)-0.01--0.01――
Aug 25, 20262026 (Q4)-0.010.00-0.01100.00% (+0.01)
Feb 26, 20262026 (Q2)―-0.01-0.01-28.57% (-0.00)
Aug 27, 20252025 (Q4)―-0.01-0.01-50.00% (-0.00)
Feb 26, 20252025 (Q2)―-0.01-0.0266.67% (+0.01)
Aug 25, 20242024 (Q4)―-0.01-0.0145.45% (+0.01)
Feb 27, 20242024 (Q2)―-0.02-4.3799.52% (+4.35)
Aug 29, 20232023 (Q4)―-0.01-0.396.28% (+0.28)
Feb 26, 20232023 (Q2)―-4.37-0.09-4808.99% (-4.28)
Aug 25, 20222022 (Q4)-0.08-0.30-0.6352.94% (+0.33)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed